Insight into diagnostics, treatment for severe C. diff infection

Issue: BCMJ, vol. 63 , No. 7 , September 2021 , Pages 280 News

Clostridioides difficile (C. diff) is the leading cause of gastroenteritis-associated death in North America. While most people affected will fully recover, new research from Vancouver Coastal Health Research Institute scientist Dr Theodore Steiner explores how to identify the roughly 25% to 35% of patients who will experience recurrent or severe infection.

The Centers for Disease Control and Prevention defines C. diff as a significant health concern because it can cause life-threatening diarrhea and inflammation of the colon. At greatest risk of becoming dangerously ill or dying due to the infection are people ages 65 and older who take antibiotics, along with individuals with a prior C. diff infection and people who are hospitalized or living in long-term care homes. Young and middle-aged adults can also be plagued by recurrent infections that cause life-altering diarrhea, abdominal cramps, and potential hospitalizations.

Dr Steiner is a professor and the head of the Division of Infectious Diseases, an associate member in the Department of Microbiology and Immunology at the University of British Columbia, and a researcher in the Immunity and Infection Research Centre. His research, published in Gastroenterology, found that CD4+ T-cell immune response to the C. diff toxins A and B was higher among patients who experienced recurrent or more severe C. diff infection compared with individuals with their first episode of C. diff. Part of the body’s immune system, CD4+ T-cells are specialists in gut-related infections. They can help fight C. diff by recruiting cytokine molecules to signal the immune system to attack the infection and to produce antibodies that neutralize the toxins, preventing them from damaging cells. A potential biomarker, the greater presence of CD4+ T-cell response to the C. diff A and B toxins could help clinicians identify which patients are more likely to recover through first-line antibiotic treatments, and which may require additional interventions.

Fecal transplantation as alternative therapy for treatment-resistant C. diff

C. diff infection occurs through ingesting the pathogen, which is found in water, soil, food, and human and animal feces. Once infection occurs, the first-line treatment is a course of antibiotics, such as vancomycin or metronidazole. These medications work by destroying bacteria in the intestines. However, they do not block the C. diff A and B pathogenic toxins that cause damaging inflammation. They also destroy healthy gut bacteria, which can create a more favorable environment for C. diff recurrence or reinfection. Patients who do not respond to at least two rounds of antibiotics may be prescribed fecal microbiota transplantation (FMT), a well-established procedure in which stool from a healthy donor is transplanted into the patient’s gastrointestinal tract.

In another study published in Gastroenterology in January 2021, Steiner found that this second-line treatment for recurrent and severe C. diff improved Th17 counts—a type of CD4+ T-cell—as well as antibodies to C. diff toxins A and B, all of which supported the greater balance of healthy gut flora essential to disease recovery.

Studies have shown a 90% global effectiveness of FMT on this patient cohort, according to Steiner. While more involved than antibiotic treatments, the Health Canada–approved intervention may be the best option for many people with a treatment-resistant infection.

Steiner is currently recruiting adults ages 18 and older with a first instance of C. diff infection for his new onset C. diff study. For more information, contact study coordinator Laura Oliveira at laura.oliveira@ubc.ca.

. Insight into diagnostics, treatment for severe C. diff infection. BCMJ, Vol. 63, No. 7, September, 2021, Page(s) 280 - News.



Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply